GLP-1 drugs have moved fast. They started as treatments for type-2 diabetes. Now they are a global health and consumer trend. In South Africa, medicines such as Ozempic and other semaglutide-based therapies are attracting wider attention.
The reason is simple. These drugs reduce appetite and support weight management. They also sit within a bigger shift towards preventive health. Some researchers are exploring wider benefits, including anti-inflammatory effects and possible links to healthy ageing. That interest is helping to pull GLP-1s into mainstream conversation.
Adoption in South Africa is still lower than in richer markets. But analysts expect growth. They point to lower-cost options and new delivery formats. Together, these changes could expand access and normalise longer-term use.
Lower-Cost Options Could Drive GLP-1 Drugs In South Africa Uptake
Price has been the biggest barrier. Injectable GLP-1s are expensive. They also require cold-chain storage, which adds friction in emerging markets. That picture may shift as generic semaglutide alternatives arrive and as oral GLP-1 pills gain approvals.
Oral formulations matter for scale. They simplify storage and logistics. They can also make treatment feel less clinical. For middle-income consumers, that convenience could be a tipping point.
Regulatory signals also support expansion. Globally, regulators are approving GLP-1s for obesity, not only diabetes. South Africa has also approved use for obesity. That widens the potential patient pool to include people who are mildly or moderately overweight.
Food Retailers May Feel The First Demand Shock
International market research suggests GLP-1 users spend less on food. Some studies report a monthly drop of around 10% in food expenditure. The biggest declines show up in calorie-dense categories. Think confectionery, snacks, and parts of fast food.
For South African retailers, that could mean volume pressure in impulse-led aisles. Brands built on sugar and convenience could face a tougher growth curve if use expands among affluent shoppers first.
Yet the story is not only negative. Evidence also points to premiumisation. People may eat less overall, but trade up when they do. Higher-quality yoghurts, fresh foods, nutrient-dense meals, and high-protein lines can benefit. That creates a split outlook. Value may shift from quantity to quality.
Alcohol Brands Face A Moderation And Premiumisation Mix
Early research also links GLP-1 use with lower alcohol cravings. The likely result is moderation rather than abstinence. Consumers may drink less often, but choose better products when they do.
That could slow growth in mass-market beer and spirits. At the same time, premium wine, craft, and higher-end spirits could prove more resilient. For producers, the strategic question becomes portfolio balance. Premium brands may become a hedge against lower volumes.
South Africa’s Economy Will Shape The Curve
South Africa’s inequality will influence how fast this plays out. In the near term, uptake of GLP-1 is more likely among higher-income consumers. That means the earliest spending shifts may show up in premium grocery baskets and lifestyle categories.
It also means GLP-1s may amplify trends already underway. Younger consumers are already drinking less. Gym culture and wellness marketing are growing. Preventive health is becoming a stronger consumer identity.
If future evidence supports broader longevity benefits, GLP-1 therapies could move even further into mainstream health planning. That would expand their impact beyond clinics into retail strategy, product development, and consumer behaviour across the economy.
- Swanepoel is an equity analyst at M&G Investments.
Read the Original Article (May require a subscription)